Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPRW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for Jasper Therapeutics, Inc., whose redeemable warrants trade on Nasdaq under the symbol JSPRW and whose voting common stock trades under JSPR. These filings include current reports on Form 8-K, registration statements such as Form S-3, and other periodic reports that describe the company’s clinical-stage biotechnology activities and capital markets transactions.
In a Form 8-K, Jasper Therapeutics reported entering into an underwriting agreement for an underwritten public offering of common stock, pre-funded warrants and common warrants. The filing details the terms of the offering, including the relationship between the warrants and the company’s voting common stock, and identifies JSPRW as redeemable warrants, each ten of which are exercisable for one share of common stock at a specified exercise price. Such documents allow investors to review the structure of the company’s securities and the intended use of proceeds, including advancement of briquilimab programs in mast-cell driven diseases and general corporate purposes.
The same Form 8-K also contains an Item 8.01 corporate update on the BEACON study in Chronic Spontaneous Urticaria. Jasper Therapeutics describes its investigation into confounded efficacy results in certain cohorts, its review of drug substance and drug product manufacturing and distribution, and its focus on clinical site activity. Filings like this provide detailed context on the company’s clinical development work and how it evaluates trial data.
On Stock Titan, these SEC filings are available with AI-powered summaries that explain key terms and highlight important sections, helping readers interpret complex documents such as 8-Ks, registration statements and other reports. Users can review filings related to offerings, warrant structures, clinical study updates and risk disclosures, while AI tools assist in identifying the most relevant information for understanding Jasper Therapeutics’ activities and the characteristics of the JSPRW warrants.
Jasper Therapeutics is offering common stock, pre‑funded warrants and accompanying common warrants while continuing clinical development of briquilimab, an anti–c‑Kit program in mast‑cell driven diseases. The prospectus reports preliminary Phase 1b/2a data across BEACON (CSU), SPOTLIGHT (CIndU) and an OLE: rapid onset of effect (responses as early as 1 week; complete responses by week 2), UAS7 reductions up to 29 points, dose‑dependent durability (complete responses lasting 4, 6 and 8 weeks at 120mg, 180mg and 240mg), and high cohort response rates (for example, 240mg single dose: 100% complete responses through 8 weeks; combined 240mg/360mg single‑dose cohorts: 8 of 9 (89%) complete responses). Safety is described as favorable with low‑grade, transient c‑Kit related AEs and no reported SAEs in several cohorts. An atypical absence of UAS7 reduction in two cohorts prompted an ongoing investigation including lot testing and site reviews after 10 patients dosed with one lot showed no UAS7 reductions; additional patients and alternative drug supply are being enrolled with results expected in late 2025. The company has 16,219,243 shares outstanding and lists common stock under symbol JSPR and public warrants under JSPRW. The prospectus discloses offering terms, use of proceeds for clinical development, tax and transfer limitations, and numerous risk factors including geopolitical and regulatory risks.